There are two major takeaways from this study: a) the minor differences in the chemistry of the various artemisinins could differentially sensitize cancer cells toward their apoptotic fate when the treatment is combined with TRAIL, and b) the ER stress response to artemisinins is a strong indicator of its potential to sensitize cancer cells to this synergistic apoptosis. The gene discussed is TNFSF10; the disease is cancer.